HPV infection and cervical disease: A review

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 51, Issue 2, 2011, Pages 103-108

  Carter, Jonathan R ^a   Ding, Zongqun ^a   Rose, Barbara R ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cervical cancer; cervical dysplasia; human papilloma virus infection

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PROTEIN P53; VIRUS ANTIBODY; VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; APPLICATION SITE DISCOMFORT; APPLICATION SITE PAIN; BASAL CELL; BASEMENT MEMBRANE; CANCER IMMUNIZATION; CHLAMYDIA TRACHOMATIS; CROSS PROTECTION; CYTOKINE RESPONSE; DRUG INDUCED HEADACHE; FATIGUE; HEALTH CARE COST; HERPES SIMPLEX VIRUS; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; MYALGIA; ORAL CONTRACEPTION; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; REINFECTION; REVIEW; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SKIN REDNESS; SMOKING; SYNCOPE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; VENOUS THROMBOEMBOLISM; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WART VIRUS;

FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 79953773080     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2010.01269.x     Document Type: Review

References (34)

1. Franco EL, Harper DM,. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394. (Pubitemid 40341489)
2. Australian Institute of Health and Welfare. Cervical Screening in Australia 2006-2007 Cancer series no. 47. Cat. no. CAN 43. Canberra: AIHW, 2009.
3. Schiffman M,. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer Cytopathol 2007; 111: 145-153. (Pubitemid 46982691)
4. Insinga RP, Glass AG, Rush BB,. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004; 191 (1): 114-120. (Pubitemid 39077963)
5. Farnsworth A, Mitchell H,. Cancer screening. Prevention of cervical cancer. eMJA 2003; 178 (12): 653-665.
6. Lowy D, Solomon D, Hildesheim A, et al. Human papillo-mavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008; 113 (7 Suppl): 1980-1993.
7. Trottier H, Franco EL,. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (Suppl 1): S4-S15.
8. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324: 17-27. (Pubitemid 38737395)
9. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518-527. (Pubitemid 36159887)
10. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87 (11): 796-802.
11. Richart RM, Barron BA,. A follow up study of patients with cervical dysplasia. Am J Obstet Gynecol 1969; 105: 386-393.
12. Clifford G, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidermiol Biomarkers Prev 2005; 14 (5): 1157-1164. (Pubitemid 40656461)
13. Safaeian M, Solomon D, Castle PE,. Cervical cancer prevention-cervical screening: science in evolution. Obstet Gynecol Clin North Am 2007; 34: 739-760. (Pubitemid 350186092)
14. Burk RD, Ho GY, Beardsley L, et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis 1996; 174 (4): 679-689. (Pubitemid 26325881)
15. Eaton DK, Lowry R, Brener ND, et al. Passive versus active parental permission in school-based survey research: does the type of permission affect prevalence estimates of risk behaviors? Eval Rev 2004; 28 (6): 564-577. (Pubitemid 39526254)
16. Brener ND, Kann L, Kinchen SA, et al. Methodology of the youth risk behavior surveillance system. MMWR Recomm Rep 2004; 53 (RR-12): 1-13.
17. Grunbaum JA, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2003. MMWR Surveill Summ 2004; 53 (2): 1-96.
18. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157 (3): 218-226. (Pubitemid 36152435)
19. Koutsky L,. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5A): 3-8. (Pubitemid 127695953)
20. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 2004; 91 (7): 1269-1274. (Pubitemid 39424786)
21. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002; 109 (1): 96-98.
22. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13 (2): 324-327. (Pubitemid 38222568)
23. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16,18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 18 (6): 1911-1919. (Pubitemid 30416152)
24. Schiller JT, Day PM, Kines RC,. Current understanding of the mechanism of HPV infection. Gynecol Oncol 2010; 118 (1 Suppl): S12-S17.
25. Stanley M,. Prophylactic HPV vaccines. J Clin Pathol 2007; 60: 961-965. (Pubitemid 47441926)
26. Stanley M,. A practitioner's guide to understanding immunity to human papillomavirus. Touch Brief 2009; 2-7.
27. Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95 (15): 1128-1137. (Pubitemid 37045391)
28. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5 (10): 705-719.
29. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res 2009; 2 (10): 868-878.
30. Bonanni P, Boccalini S, Bechini A,. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27 (Suppl 1): A46-A53.
31. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302 (7): 750-757.
32. Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373 (9679): 1949-1957.
33. Rodríguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102 (5): 315-324.
34. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196 (15): 1438-1446.